Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
BACKGROUND
The real impact of bevacizumab maintenance as single agent in metastatic colorectal cancer (mCRC) remains unclear. SAKK-41/06 and PRODIGE-9 failed to demonstrate the non-inferiority and superiority of bevacizumab versus no maintenance, respectively, while AIO-KRK-0207 showed the non-inferiority of maintenance bevacizumab versus bevacizumab and fluoropyrimidines for time to strategy failure.


METHODS
Bibliography electronic databases (PubMed, MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials) were searched for English published clinical trials prospectively randomizing mCRC patients to receive bevacizumab maintenance or not after first-line chemotherapy plus bevacizumab. Individual patients' data (IPD) were provided by investigators for all included trials. Primary end-points were progression-free survival (PFS) and overall survival (OS), both from the start of induction and maintenance. Univariate and multivariate analyses for PFS and OS were performed.


RESULTS
Three phase III studies - PRODIGE-9, AIO-KRK-0207 and SAKK-41/06 - were included. Considering the different timing of randomization, IPD of patients not progressed during induction and starting maintenance phase entered the analysis. 909 patients were included, 457 (50%) received bevacizumab maintenance. Median PFS from induction start was 9.6 and 8.9 months in bevacizumab group versus no maintenance group, respectively (HR 0.78; 95%CI: 0.68-0.89; p < 0.0001). Subgroups analysis for PFS showed a significant interaction according for RAS status (p = 0.048), with a maintenance benefit limited to RAS wild-type patients. No difference in terms of OS was observed.


CONCLUSIONS
Despite the statistically significant PFS improvement for bevacizumab maintenance, the absolute benefit appears limited. Subgroup analysis shows a differential effect of bevacizumab maintenance in favor of RAS wild-type patients. Considering these results, maintenance therapy with fluoropyrimidine with or without bevacizumab remains the first option. Single agent bevacizumab maintenance can be considered in selected cases, such as cumulative toxicity or patient's refusal, in particular for RAS wild-type patients.
['Salvatore|Lisa|L|', 'Bria|Emilio|E|', 'Sperduti|Isabella|I|', 'Hinke|Axel|A|', 'Hegewisch-Becker|Susanna|S|', 'Aparicio|Thomas|T|', 'Le Malicot|Karine|K|', 'Boige|Valérie|V|', 'Koeberle|Dieter|D|', 'Baertschi|Daniela|D|', 'Dietrich|Daniel|D|', 'Tortora|Giampaolo|G|', 'Arnold|Dirk|D|']
D000074322:Antineoplastic Agents, Immunological D000068258:Bevacizumab D017326:Clinical Trials, Phase III as Topic D015179:Colorectal Neoplasms D006801:Humans D060046:Maintenance Chemotherapy D011379:Prognosis
Bevacizumab Maintenance Metastatic colorectal cancer Meta-analysis